These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 8833208

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
    Bone HG, Downs RW, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ.
    J Clin Endocrinol Metab; 1997 Jan; 82(1):265-74. PubMed ID: 8989272
    [Abstract] [Full Text] [Related]

  • 3. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 4. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial.
    Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL, fracture intervention trial.
    Diabetes Care; 2004 Jul; 27(7):1547-53. PubMed ID: 15220226
    [Abstract] [Full Text] [Related]

  • 5. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 6. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
    Hosking D, Adami S, Felsenberg D, Andia JC, Välimäki M, Benhamou L, Reginster JY, Yacik C, Rybak-Feglin A, Petruschke RA, Zaru L, Santora AC.
    Curr Med Res Opin; 2003 Mar; 19(5):383-94. PubMed ID: 13678475
    [Abstract] [Full Text] [Related]

  • 7. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 8. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
    Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Ortolani S.
    Osteoporos Int; 1993 May; 3 Suppl 3():S21-7. PubMed ID: 8298199
    [Abstract] [Full Text] [Related]

  • 9. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
    Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP, Rosenberg E, Denker AE.
    Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 11. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
    Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.
    Ann Intern Med; 2002 Dec 03; 137(11):875-83. PubMed ID: 12458987
    [Abstract] [Full Text] [Related]

  • 12. An open-label extension study of alendronate treatment in elderly women with osteoporosis.
    Downs RW, Bone HG, McIlwain H, Baker MZ, Yates AJ, Lombardi A, Krupa D, Harning R.
    Calcif Tissue Int; 1999 Jun 03; 64(6):463-9. PubMed ID: 10341016
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ.
    Aging (Milano); 2000 Feb 03; 12(1):1-12. PubMed ID: 10746426
    [Abstract] [Full Text] [Related]

  • 14. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 03; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 15. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A.
    Bone; 1995 Oct 03; 17(4):383-90. PubMed ID: 8573412
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
    Deng J, Feng Z, Li Y, Pan T, Li Q, Zhao C.
    Medicine (Baltimore); 2018 Nov 03; 97(47):e13341. PubMed ID: 30461654
    [Abstract] [Full Text] [Related]

  • 17. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M.
    N Engl J Med; 1995 Nov 30; 333(22):1437-43. PubMed ID: 7477143
    [Abstract] [Full Text] [Related]

  • 18. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
    Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC.
    Am J Med; 1996 Nov 30; 101(5):488-501. PubMed ID: 8948272
    [Abstract] [Full Text] [Related]

  • 19. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, Marques-Neto JF, Gaines KA, Verbruggen N, Melton ME.
    Clin Drug Investig; 2006 Nov 30; 26(2):63-74. PubMed ID: 17163237
    [Abstract] [Full Text] [Related]

  • 20. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 30; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.